Seelos therapeutics announces notice of delisting from nasdaq and transfer of listing to over-the-counter market

New york , oct. 15, 2024 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel) ("seelos" or the "company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that on october 14, 2024, seelos therapeutics, inc. (the "company") received notice that the nasdaq hearings panel (the "panel") had determined to delist the company's common stock from the nasdaq stock market llc ("nasdaq") due to the company's failure to comply with the minimum stockholder's equity requirement under nasdaq listing rule 5550(b)(1) (the "equity standard rule"). as previously disclosed, the panel had provided the company until october 11, 2024, to regain compliance with the equity standard rule.
SEEL Ratings Summary
SEEL Quant Ranking